Syon Capital LLC Has $5.75 Million Stake in AbbVie Inc. $ABBV

Syon Capital LLC grew its stake in AbbVie Inc. (NYSE:ABBV) by 16.4% during the 3rd quarter, HoldingsChannel reports. The firm owned 24,839 shares of the company’s stock after acquiring an additional 3,491 shares during the quarter. Syon Capital LLC’s holdings in AbbVie were worth $5,751,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Ellenbecker Investment Group boosted its holdings in AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after buying an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA boosted its position in shares of AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after buying an additional 45 shares during the period. Matthew Goff Investment Advisor LLC boosted its holdings in AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after purchasing an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC raised its holdings in AbbVie by 2.2% during the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after acquiring an additional 45 shares in the last quarter. Finally, Willner & Heller LLC boosted its holdings in shares of AbbVie by 0.6% in the 3rd quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after buying an additional 46 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the subject of a number of research analyst reports. BMO Capital Markets restated an “outperform” rating and set a $258.00 price objective on shares of AbbVie in a report on Thursday, January 15th. Scotiabank assumed coverage on AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective for the company. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Finally, Piper Sandler lifted their target price on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $251.56.

AbbVie Price Performance

NYSE ABBV opened at $232.69 on Wednesday. The stock has a market capitalization of $411.25 billion, a PE ratio of 98.60, a P/E/G ratio of 0.81 and a beta of 0.35. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company’s 50 day simple moving average is $223.93 and its two-hundred day simple moving average is $221.63.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.AbbVie’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period last year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.